Novartis has announced plans to build a flagship manufacturing hub in North Carolina, creating 700 jobs and adding major capacity for U.S. drug production. The project is part of a wider $23 billion U.S. infrastructure investment aimed at bringing more of the company’s key medicines fully onshore.
The hub will span several sites across the state’s Research Triangle. In Durham, Novartis will construct two new facilities focused on biologics manufacturing and sterile packaging. A separate site in nearby Morrisville will handle solid dosage tablets and capsules, including packaging. The company will also expand its existing Durham campus to add sterile filling of biologics into syringes and vials, creating a tightly integrated network of plants.
Together, the sites are expected to cover more than 700,000 square feet once they come online between 2027 and 2028. The North Carolina hub will support medicines across oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic disease areas. For Novartis, the goal is clear: build end-to-end U.S. manufacturing so core therapies can be produced, filled, and packaged domestically, then shipped nationwide at scale.
For IndustryTap readers, the project highlights several important trends. First, global pharma is still pouring money into advanced manufacturing hubs that combine biologics, solid-dose, and sterile operations in one region. Second, the design implies high levels of automation, cleanroom investment, and digital process control to keep complex product flows synchronized. Engineering firms, equipment suppliers, and construction partners in the Triangle will be watching the contract pipeline closely.
There is also a workforce dimension. The project is expected to create 700 direct jobs and more than 3,000 indirect roles across the supply chain by 2030. That means demand for process engineers, validation specialists, facility managers, and automation talent will keep rising in an already competitive market. Local training providers and universities are likely to deepen their pharma-focused programs to match.
What to watch next
Readers should track permitting milestones, construction timelines, and early details on automation and sustainability features at the new sites. As Novartis builds out the hub, it may become a reference model for how large pharma companies reshape supply chains around regional, end-to-end manufacturing campuses in the U.S.
